Onconic Therapeutics Inc. (KOSDAQ:476060)

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2022	FY 2021
Period Ending	Dec 31, 2022	Dec 31, 2021
Biotechnology	95.00M	60.00M
Biotechnology Growth	58.33%	-
Total	95.00M	60.00M
Total Growth	58.33%	-

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2022	FY 2021
Period Ending	Dec 31, 2022	Dec 31, 2021
South Korea	95.00M	60.00M
South Korea Growth	58.33%	-
Total	95.00M	60.00M
Total Growth	58.33%	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 27, 2026

Data Sources Report a data error